
Torpedo Therapeutics develops high-precision, closed-loop deep brain stimulation (DBS) devices to treat neurological disorders such as Parkinson's disease, Essential Tremor, Dystonia, and drug-resistant Epilepsy. Their technology uses micro- and nano-fabrication to create micro-electrode leads that are 150 times smaller than existing DBS electrodes, enabling stimulation with single neuron precision and reducing side effects caused by off-target stimulation. The system integrates an electronic chip for signal readout and stimulation control, replacing bulky implantable pulse generators. A machine learning-driven data analysis platform automates adjustment of stimulation parameters based on continuous neural activity sensing, improving long-term efficacy and reducing the need for clinical reprogramming. This innovative approach positions Torpedo Therapeutics as a leader in next-generation neuromodulation therapies with potential for better patient outcomes and reduced surgical interventions.

Torpedo Therapeutics develops high-precision, closed-loop deep brain stimulation (DBS) devices to treat neurological disorders such as Parkinson's disease, Essential Tremor, Dystonia, and drug-resistant Epilepsy. Their technology uses micro- and nano-fabrication to create micro-electrode leads that are 150 times smaller than existing DBS electrodes, enabling stimulation with single neuron precision and reducing side effects caused by off-target stimulation. The system integrates an electronic chip for signal readout and stimulation control, replacing bulky implantable pulse generators. A machine learning-driven data analysis platform automates adjustment of stimulation parameters based on continuous neural activity sensing, improving long-term efficacy and reducing the need for clinical reprogramming. This innovative approach positions Torpedo Therapeutics as a leader in next-generation neuromodulation therapies with potential for better patient outcomes and reduced surgical interventions.